| 1 |
Sato Y, Okamoto K, Kida Y, Mitsui Y, Kawano Y, Sogabe M, Miyamoto H, Takayama T. Overview of Chemotherapy for Gastric Cancer. J Clin Med 2023;12. [PMID: 36835872 DOI: 10.3390/jcm12041336] [Reference Citation Analysis]
|
| 2 |
Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S, Kwang Yang H, Ji J, Baba H, Kitagawa Y, Morita S, Nishiyama M, Kodera Y; CONVO‐GC‐1 Study Group, Federation of Asian Clinical Oncology (FACO). International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1). Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Hirahara N, Matsubara T, Kaji S, Yamamoto T, Hyakudomi R, Takai K, Ishitobi K, Uchida Y, Tajima Y. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. BMC Cancer 2021;21:1073. [PMID: 34598694 DOI: 10.1186/s12885-021-08795-4] [Reference Citation Analysis]
|
| 4 |
Tsuchida K, Sato T, Aoyama T, Atsumi Y, Kano K, Maezawa Y, Kazama K, Numata M, Yamada T, Tamagawa H, Murakami H, Oshima T, Saeki H, Cho H, Yukawa N, Yamamoto Y, Masuda M, Rino Y. Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer. Jpn J Clin Oncol 2021;51:371-8. [PMID: 33283236 DOI: 10.1093/jjco/hyaa221] [Reference Citation Analysis]
|
| 5 |
Hosoda K, Ushiku H, Katada C, Ishido K, Niihara M, Sakuraya M, Araki I, Washio M, Harada H, Yamashita K, Hiki N. Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer. Langenbecks Arch Surg 2021;406:1045-55. [PMID: 33745003 DOI: 10.1007/s00423-021-02153-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Pourghasemian M, Danandeh Mehr A, Molaei M, Habibzadeh A. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. Asian Pac J Cancer Prev 2020;21:2337-41. [PMID: 32856863 DOI: 10.31557/APJCP.2020.21.8.2337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 7 |
Hayashi T, Yoshikawa T, Sakamaki K, Nishikawa K, Fujitani K, Tanabe K, Misawa K, Matsui T, Miki A, Nemoto H, Fukunaga T, Kimura Y, Hihara J. Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for advanced gastric cancer. Ann Gastroenterol Surg 2020;4:540-8. [PMID: 33005849 DOI: 10.1002/ags3.12352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 8 |
Hosoda K, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Sato T, Tajima H, Kaizu T, Kosaka Y, Kato H, Sengoku N, Tanaka K, Naito T, Kumamoto Y, Sangai T, Tanabe S, Koizumi W, Yamashita K, Hiki N. Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial. Langenbecks Arch Surg 2020;405:777-85. [PMID: 32617667 DOI: 10.1007/s00423-020-01924-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Nakagawa T, Sato Y, Tanahashi T, Mitsui Y, Kida Y, Fujino Y, Hirata M, Kitamura S, Miyamoto H, Okamoto K, Muguruma N, Bando Y, Takayama T. JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8. Gastric Cancer 2020;23:426-36. [PMID: 31677131 DOI: 10.1007/s10120-019-01024-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 10 |
Hosoda K, Azuma M, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Tanabe S, Koizumi W, Yamashita K, Hiki N. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Int J Clin Oncol 2020;25:1090-7. [PMID: 32124094 DOI: 10.1007/s10147-020-01638-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasako M, Morita S, Nomura T, Yamada M, Fujiwara Y, Kimura Y, Ikeda A, Kadokawa Y, Sano T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer 2020;23:293-9. [PMID: 31515693 DOI: 10.1007/s10120-019-01007-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 12 |
Zhang F, Huang X, Song Y, Gao P, Zhou C, Guo Z, Shi J, Wu Z, Wang Z. Conversion Surgery for Stage IV Gastric Cancer. Front Oncol 2019;9:1158. [PMID: 31788445 DOI: 10.3389/fonc.2019.01158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Nakamura M, Ojima T, Nakamori M, Katsuda M, Tsuji T, Hayata K, Kato T, Yamaue H. Conversion Surgery for Gastric Cancer with Peritoneal Metastasis Based on the Diagnosis of Second-Look Staging Laparoscopy. J Gastrointest Surg 2019;23:1758-66. [PMID: 30264385 DOI: 10.1007/s11605-018-3983-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 14 |
Maeda O, Ando Y. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World J Gastrointest Oncol 2019; 11(7): 518-526 [PMID: 31367271 DOI: 10.4251/wjgo.v11.i7.518] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 15 |
Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4:501-10. [PMID: 31101534 DOI: 10.1016/S2468-1253(19)30083-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 16 |
Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, Ema A, Ushiku H, Wada T, Washio M, Watanabe A, Higuchi K, Tanabe S, Koizumi W, Watanabe M, Yamashita K. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer 2019;22:598-606. [PMID: 30284080 DOI: 10.1007/s10120-018-0884-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 17 |
Sakaguchi M, Shimoike N, Akagawa S, Kanaya S. Strategy for treatment of stage IV human epidermal growth factor 2-positive gastric cancer: a case report. J Med Case Rep. 2019;13:42. [PMID: 30791934 DOI: 10.1186/s13256-019-2001-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Okabe H, Hata H, Hosogi H, Ueda S, Ota S, Kinjo Y, Hoshino N, Hisamori S, Tsunoda S, Obama K, Sakai Y; The Kyoto University Surgical Oncology Group (KUSOG). A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06). Ann Surg Oncol 2019;26:1779-86. [DOI: 10.1245/s10434-019-07229-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Shinkai M, Imano M, Chiba Y, Iwama M, Shiraisi O, Yasuda A, Tsubaki M, Nishida S, Kimura Y, Yasuda T. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. J Surg Oncol 2019;119:56-63. [PMID: 30444009 DOI: 10.1002/jso.25295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 20 |
Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamaguchi K, Fujikawa K, Nobuoka T, Okamoto K, Miyamoto H, Muguruma N, Takemasa I, Takayama T. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 2019;83:161-7. [PMID: 30406285 DOI: 10.1007/s00280-018-3719-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 21 |
Hosoda K, Watanabe M, Yamashita K. Re-emerging role of macroscopic appearance in treatment strategy for gastric cancer. Ann Gastroenterol Surg 2019;3:122-9. [PMID: 30923781 DOI: 10.1002/ags3.12218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer 2018;21:802-10. [PMID: 29372461 DOI: 10.1007/s10120-018-0794-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 23 |
Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, Miki A, Nemoto H, Sakamaki K, Fukunaga T, Kimura Y, Hirabayashi N, Yoshikawa T. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol 2017;28:1876-81. [PMID: 28486692 DOI: 10.1093/annonc/mdx236] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 24 |
Hosoda K, Yamashita K, Tsuruta H, Moriya H, Mieno H, Ema A, Washio M, Watanabe M. Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy. Oncol Lett 2018;15:1200-10. [PMID: 29399174 DOI: 10.3892/ol.2017.7441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 25 |
Ohnuma H, Sato Y, Hirakawa M, Kikuchi S, Miyanishi K, Sagawa T, Takahashi Y, Nobuoka T, Okamoto K, Miyamoto H, Takemasa I, Takayama T, Kato J. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemother Pharmacol. 2018;81:539-548. [PMID: 29383482 DOI: 10.1007/s00280-018-3523-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 26 |
Liu M, Hu G, Wang Y, Guo J, Liu L, Han X, Wang Z. Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. Onco Targets Ther 2018;11:375-81. [PMID: 29398919 DOI: 10.2147/OTT.S149624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 27 |
Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer 2017;17:837. [PMID: 29221445 DOI: 10.1186/s12885-017-3850-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 28 |
Hosokawa A, Ando T, Ogawa K, Ueda A, Yoshita H, Mihara H, Fujinami H, Kajiura S, Yabushita K, Horikawa N, Kobayashi Y, Yoshioka A, Origasa H, Sugiyama T. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer. Am J Clin Oncol 2018;41:977-81. [PMID: 28930775 DOI: 10.1097/COC.0000000000000405] [Reference Citation Analysis]
|
| 29 |
Ushiku H, Yamashita K, Ema A, Minatani N, Kikuchi M, Kojo K, Yokoi K, Tanaka T, Nishizawa N, Ishii S, Hosoda K, Moriya H, Mieno H, Katada N, Kikuchi S, Katoh H, Watanabe M. DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer. Gastric Cancer 2017;20:784-92. [PMID: 28243814 DOI: 10.1007/s10120-017-0697-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 30 |
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.CD004064.pub4] [Cited by in Crossref: 153] [Cited by in F6Publishing: 283] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 31 |
Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, Takahashi M, Ito J, Nakajima M, Yamaguchi S, Miyachi K, Kato H. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol 2017;34:139. [PMID: 28707042 DOI: 10.1007/s12032-017-0997-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Tahara T, Shibata T, Okubo M, Yoshida D, Kawamura T, Horiguchi N, Ishizuka T, Nagasaka M, Nakagawa Y, Ohmiya N. Histological evaluations of primary lesions are independently associated with prognosis in patients with gastric cancer who receive neoadjuvant chemotherapy. Oncol Lett 2017;13:4892-6. [PMID: 28599492 DOI: 10.3892/ol.2017.6040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 33 |
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer 2017;20:517-26. [PMID: 27553665 DOI: 10.1007/s10120-016-0633-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 34 |
Yamashita K, Ema A, Hosoda K, Mieno H, Moriya H, Katada N, Watanabe M. Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy. World J Gastrointest Oncol 2017; 9(4): 166-175 [PMID: 28451064 DOI: 10.4251/wjgo.v9.i4.166] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 35 |
Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, Komori S, Yoshida T, Tanabe S, Koizumi W, Katada N, Watanabe M. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today 2017;47:1249-58. [PMID: 28365892 DOI: 10.1007/s00595-017-1512-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 36 |
Tahara T, Shibata T, Okubo M, Kawamura T, Horiguchi N, Yoshida D, Ishizuka T, Nagasaka M, Nakagawa Y, Ohmiya N. Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy. PLoS One 2017;12:e0173663. [PMID: 28288188 DOI: 10.1371/journal.pone.0173663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 37 |
Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer 2017;20:322-31. [PMID: 27299887 DOI: 10.1007/s10120-016-0619-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 38 |
Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 39 |
Ishido K, Higuchi K, Azuma M, Sasaki T, Tanabe S, Katada C, Yano T, Wada T, Koizumi W; Kitasato Digestive Disease & Oncology Group. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002). Anticancer Drugs 2016;27:884-90. [PMID: 27254283 DOI: 10.1097/CAD.0000000000000385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 40 |
Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol 2016;142:1727-38. [PMID: 27256004 DOI: 10.1007/s00432-016-2184-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 41 |
Takiguchi S, Miyazaki Y, Shinno N, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Mori M, Doki Y. Laparoscopic mediastinal dissection via an open left diaphragm approach for advanced Siewert type II adenocarcinoma. Surg Today 2016;46:129-34. [PMID: 26374333 DOI: 10.1007/s00595-015-1247-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 42 |
Ito S, Ito Y, Misawa K, Shimizu Y, Kinoshita T. Neoadjuvant chemotherapy followed by surgery in gastric cancer patients with extensive lymph node metastasis. World J Clin Oncol 2015; 6(6): 291-294 [PMID: 26677442 DOI: 10.5306/wjco.v6.i6.291] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 43 |
Takiguchi S, Miyazaki Y, Murakami K, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Mori M, Doki Y. Laparoscopic lymphadenectomy around the left renal vein (16a2lat) by tunneling under the pancreas for advanced Siewert type II adenocarcinoma. Surg Today 2016;46:1108-13. [PMID: 26482844 DOI: 10.1007/s00595-015-1264-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 44 |
Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015;26:149-156. [PMID: 25416687 DOI: 10.1093/annonc/mdu496] [Cited by in Crossref: 72] [Cited by in F6Publishing: 83] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 45 |
Yamashita K, Ushiku H, Katada N, Hosoda K, Moriya H, Mieno H, Kikuchi S, Hoshi K, Watanabe M. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test. Eur J Surg Oncol. 2015;41:1324-1332. [PMID: 26251341 DOI: 10.1016/j.ejso.2015.05.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 46 |
Mitsui Y, Sato Y, Miyamoto H, Fujino Y, Takaoka T, Miyoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T. Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemother Pharmacol. 2015;76:375-382. [PMID: 26099968 DOI: 10.1007/s00280-015-2807-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 47 |
Migita K, Nashimoto A, Yabusaki H, Matsuki A, Aizawa M. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. Int J Clin Oncol 2016;21:102-9. [DOI: 10.1007/s10147-015-0851-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 48 |
Watanabe A, Kida M, Miyazawa S, Iwai T, Okuwaki K, Kaneko T, Yamauchi H, Takezawa M, Imaizumi H, Koizumi W. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer. World J Gastroenterol 2015; 21(19): 5979-5984 [PMID: 26019463 DOI: 10.3748/wjg.v21.i19.5979] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 49 |
Cho H, Nakamura J, Asaumi Y, Yabusaki H, Sakon M, Takasu N, Kobayashi T, Aoki T, Shiraishi O, Kishimoto H, Nunobe S, Yanagisawa S, Suda T, Ueshima S, Matono S, Maruyama H, Tatsumi M, Seya T, Tanizawa Y, Yoshikawa T. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature. Ann Surg Oncol 2015;22:787-92. [PMID: 25223927 DOI: 10.1245/s10434-014-4084-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 50 |
Fang FQ, Liu MZ, Tong Y, Liu TT, Zhang J. A clinical study of DOF regimen vs SOX regimen as first-line treatment in patients with advanced gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(31): 4830-4834 [DOI: 10.11569/wcjd.v22.i31.4830] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 51 |
Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: A borderline resectable cancer? Surg Today. 2015;45:1082-1090. [PMID: 25366353 DOI: 10.1007/s00595-014-1067-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 52 |
Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, Sakuramoto S, Kikuchi S, Watanabe M. Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today. 2015;45:68-77. [PMID: 25352012 DOI: 10.1007/s00595-014-1060-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 53 |
Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2014;17:213-25. [PMID: 24048758 DOI: 10.1007/s10120-013-0297-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 54 |
Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 55 |
Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 56 |
Kim BH, Eom KY, Kim JS, Kim HH, Park DJ. Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer. Radiat Oncol J 2013;31:147-54. [PMID: 24137560 DOI: 10.3857/roj.2013.31.3.147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 57 |
Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Crit Rev Oncol Hematol. 2013;88:416-426. [PMID: 23764501 DOI: 10.1016/j.critrevonc.2013.05.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 58 |
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol. 2013;71:789-797. [PMID: 23338051 DOI: 10.1007/s00280-013-2073-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 59 |
Tunceroglu A, Jabbour SK. Gastric cancer: past accomplishments, present approaches and future aspirations. Clinical Practice 2013;10:47-77. [DOI: 10.2217/cpr.12.82] [Reference Citation Analysis]
|
| 60 |
Kimura Y, Yano H, Imamura H, Fujitani K, Imano M, Tokunaga Y, Matsuoka M, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer. Jpn J Clin Oncol 2013;43:125-31. [PMID: 23225911 DOI: 10.1093/jjco/hys204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 61 |
Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 2012;13:1943-59. [PMID: 22860709 DOI: 10.1517/14656566.2012.709234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 62 |
Katayama H, Ito S, Sano T, Takahari D, Mizusawa J, Boku N, Tsuburaya A, Terashima M, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. Jpn J Clin Oncol 2012;42:556-9. [PMID: 22525210 DOI: 10.1093/jjco/hys054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 63 |
Sato T, Rino Y, Yamada R, Oshima T, Masuda M. Neoadjuvant Chemotherapy of Resectable Advanced Gastric Cancer. JJCS 2012;37:197-204. [DOI: 10.4030/jjcs.37.197] [Reference Citation Analysis]
|
| 64 |
Yoshikawa T, Kuwabara H, Aoyama T, Mikayama Y, Hayashi T, Ogata T, Cho H, Tsuburaya A, Morita T, Sakamoto J. Future Development of Adjuvant Chemotherapy for Gastric Cancer. JJCS 2012;37:686-690. [DOI: 10.4030/jjcs.37.686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
